Profile Image

Dr Kathryn Skelding

Lecturer

School of Biomedical Sciences and Pharmacy (Medical Biochemistry)

Dr Kathryn Skelding - Career Highlights

From an early age Dr Kathryn Skelding was fascinated by how the body works, and by how you could treat a variety of diseases and conditions.  

"I always wanted to know why – why does that disease develop? How does that treatment work?", the cancer researcher and lecturer details. 

"So it was just natural that I would become a medical researcher who investigates the causes of diseases, so that we can develop new and better treatments".  This curiosity continued throughout her university studies, where she graduated with first class Honours and the University Medal in Biomedical Science.

Her choice of research field was greatly influenced by personal experience.  Several people close to Dr Skelding have been affected by cancer. 

"While it's well-known that side effects are associated with chemotherapy, it's only when you actually see what these drugs do to someone that it really hits home how toxic they are", she says. She studies how cancer cells function so that she can better understand how cancer cells grow, spread and develop resistance to chemotherapy drugs.

"If scientists can better understand these processes, we can develop new treatments for cancer that are more cancer-cell specific and have fewer side effects", she says.  "My lab focuses on a molecule that is present in high amounts in leukaemia cells, and that we have shown is involved in controlling cancer cell growth and survival."

This molecule is a protein called BAALC (brain and acute leukaemia, cytoplasmic), and its presence is associated with aggressive disease that is more likely to recur, and also indicate that chemotherapeutic drugs may not be effective against these leukaemia cells. This work has led to Dr Skelding developing a new inhibitor for this molecule. This inhibitor is currently being developed with Newcastle Innovation.

This year, Skelding was the recipient of a $200,000 grant from the Cure Cancer Australia Foundation to help develop this new treatment for acute myeloid leukaemia (AML). Such treatments are desperately needed, as currently only about a quarter of patients diagnosed with AML will survive for five years.

Skelding works closely with her colleagues in the University's Priority Research Centre for Cancer, and through her association with the Hunter Medical Research Institute (HMRI) she has established important links and relationships with clinical oncologists.

Skelding is no stranger to the development of new targeted therapies for cancer.  Her doctoral studies examined the use of novel oncolytic viruses as treatments for breast cancer, and were funded by a National Breast Cancer Foundation Scholarship. One of these agents is currently in Phase II clinical trials for the treatment of melanoma, breast and prostate cancer.

She hopes that her newly funded research will lead to a new treatment for leukaemia which will improve patient survival rates and quality of life.

Dr Kathryn Skelding - Career Highlights

From an early age Dr Kathryn Skelding was fascinated by how the body works, and by how you could treat a variety of diseases and conditions. "I always wanted to know why – why does that disease develop? How does…

Read more

Career Summary

Biography

Dr Skelding is an early career researcher, who was appointed to a full-time continuing lecturing position at the start of 2012.  Her research focuses on understanding cancer cell biology, specifically how cancer cells proliferate, metastasise, and develop resistance to chemotherapeutics. If these processes can be better understood, new targeted anti-cancer therapies can be discovered.  Dr Skelding's PhD investigated the use of oncolytic viruses as novel anti-cancer agents, and was funded by a National Breast Cancer Foundation (NBCF) Scholarship, as well as the commercial company, Viralytics Ltd.

During her PhD, Dr Skelding developed new clinically relevant mouse models of spontaneously metastasising breast cancer, which allowed her to examine the pre-clinical effectiveness of novel viral therapies for cancer, both as single agents, and in combination with currently approved chemotherapeutic agents.

Additionally, the research undertaken throughout Dr Skelding's PhD has led to the commencement of a Phase II clinical trial in the use of this virus (CAVATAK) as an intravenous treatment for melanoma, breast, and prostate cancer. In her post-doctoral studies, Dr Skelding further applied her background in cell biology to examine signal transduction pathways and the role of targeting in regulating CaMKII (calcium/calmodulin-stimulated protein kinase II) function in neuronal cells.

Since completing her post-doctoral studies in 2012, she has established her own research group that focuses on better understanding cell signalling in cancer, with a view to developing new therapies that are cancer cell-specific and suitable for the treatment of a range of cancers, with a focus on leukaemias (specifically acute myeloid leukaemia, and childhood acute lymphoblastic leukaemia), breast cancer and prostate cancer. 

Dr Skelding has received several awards throughout her research career, including the International Society for Neurochemistry Travel Award (2011), Best Early Career Researcher Speaker at the Hunter Medical Research Institute Cancer Research Program Symposium (2010), Best Speaker at the University of Newcastle Graduate Student’s Day (2006), University Medal in Biomedical Science (2003), the University of Newcastle Vice Chancellor’s Award for Academic Excellence (2000), and numerous undergraduate and post-graduate training scholarships. Due to work completed throughout her PhD, the Hon Roslyn Kelly (Chair of the National Breast Cancer Foundation Board of Trustees) nominated Dr Skelding for a Fresh Science Award in 2006, for which she was short-listed.

Dr Skelding's overarching research aim is improve patient outcomes and quality of life, by translating her research findings into the clinic.

Research Expertise
Dr Skelding's research interests focus on examining signal transduction pathways and the role of targeting in regulating cancer cell proliferation, invasion/migration and chemotherapy resistance, so that new targets for controlling these cellular functions can be identified. Using a variety of molecular, biochemical and cellular techniques (including siRNA and overexpression transfection of cancer and normal cell lines, western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, proliferation assays, cell survival assays, flow cytometry, invasion and migration assays), she has identified new pathways involved in these processes. Additionally, she has developed novel inhibitors that can target these pathways. Dr Skelding is currently examining the efficacy of these new drugs in a range of cancer types, including acute myeloid and lymphoblastiac leukaemia, breast cancer and prostate cancer.

Teaching Expertise
Cell biology Biochemistry Molecular biology

Administrative Expertise
Dr Skelding is a member of the University of Newcastle Faculty of Health Occupational Health and Safety Committee, and has been on the organising committee for several conferences and symposium days. Dr Skelding is also on the editorial board of the International Journal, Calcium Signalling.

Collaborations
Dr Skelding's interest in the regulation of protein function via targeting has led to her forming local, national, and international collaborations to investigate the role of protein phosphorylation in heart disease and following stroke, as well as investigating protein phosphatase 2A (PP2A) reactivators as new treatments for leukaemia and breast cancer.


Qualifications

  • PhD, University of Newcastle

Keywords

  • Anti-cancer drugs
  • Biochemistry
  • Breast cancer
  • Cancer
  • Cancer cell biology
  • Cell cycle
  • Enzymes
  • Genetics
  • Leukaemia
  • Molecular Targeting
  • Prostate cancer
  • Protein Phosphorylation
  • Proteins

Languages

  • English (Fluent)

Fields of Research

CodeDescriptionPercentage
060103Cell Development, Proliferation and Death25
111201Cancer Cell Biology50
111204Cancer Therapy (excl. Chemotherapy and Radiation Therapy)25

Professional Experience

UON Appointment

DatesTitleOrganisation / Department
1/01/2015 - LecturerUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Academic appointment

DatesTitleOrganisation / Department
1/01/2013 - Editorial Board - Calcium SignallingCalcium Signalling
Australia
1/01/2013 - Membership - Australian Society of Biochemistry and Molecular BiologyAustralian Society of Biochemistry and Molecular Biology
Australia
1/01/2012 - LecturerUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/01/2008 - Membership - Australian Neuroscience SocietyAustralian Neuroscience Society (ANS)
Australia
1/07/2007 - 1/12/2011Research AssociateUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Invitations

Speaker

YearTitle / Rationale
2015CaMKII – a new target for regulating breast cancer cell invasion and migration
Organisation: 8th Annual World Cancer Conference
2012Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253
Organisation: APSN and JSN Description: Invited presentation
2010Importance of community support in performing medical research
Organisation: NBCF Description: Invited presentation
2007Use of a common cold-producing virus as a potential treatment for breast cancer
Organisation: NBCF Description: Invited presentation
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

YearCitationAltmetricsLink
2012Skelding KA, Rostas JA, 'The role of molecular regulation and targeting in regulating calcium/calmodulin stimulated protein kinases', Calcium Signaling, Springer New York LLC, New York, NY 703-730 (2012) [B1]
CitationsScopus - 4Web of Science - 4
Co-authorsJohn Rostas

Journal article (15 outputs)

YearCitationAltmetricsLink
2014Skelding KA, Arellano JM, Powis DA, Rostas JA, 'Excitotoxic stimulation of brain microslices as an in vitro model of stroke.', J Vis Exp, e51291 (2014) [C1]
DOI10.3791/51291Author URL
Co-authorsJohn Rostas
2014Hoffman A, Carpenter H, Kahl R, Watt LF, Dickson PW, Rostas JAP, et al., 'Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition', Cellular Signalling, 26 748-756 (2014) [C1]

Calcium/calmodulin-stimulated protein kinase II (CaMKII) is a multi-functional serine/threonine protein kinase that controls a range of cellular functions, including proliferation. The biological properties of CaMKII are regulated by multi-site phosphorylation and targeting via interactions with specific proteins. To investigate the role specific CaMKII phosphorylation sites play in controlling cell proliferation and cell cycle progression, we examined phosphorylation of CaMKII at two sites (T253 and T286) at various stages of the cell cycle, and also examined the effects of overexpression of wild-type (WT), T286D phosphomimic, T253D phosphomimic and T253V phosphonull forms of CaMKIIa in MDA-MB-231 breast cancer and SHSY5Y neuroblastoma cells on cellular proliferation and cell cycle progression. We demonstrate herein that whilst there is no change in total CaMKII expression or T286 phosphorylation throughout the cell cycle, a marked dephosphorylation of CaMKII at T253 occurs during the G2 and/or M phases. Additionally, we show by molecular inhibition, as well as pharmacological activation, that protein phosphatase 2A (PP2A) is the phosphatase responsible for this dephosphorylation. Furthermore, we show that inducible overexpression of WT, T286D and T253V forms of CaMKIIa in MDA-MB-231 and SHSY5Y cells increases cellular proliferation, with no alteration in cell cycle profiles. By contrast, overexpression of a T253D phosphomimic form of CaMKIIa significantly decreases proliferation, and cells accumulate in mitosis, specifically in metaphase. Taken together, these results strongly suggest that the dephosphorylation of CaMKII at T253 is involved in controlling the cell cycle, specifically the metaphase-anaphase transition. © 2014 Elsevier Inc.

DOI10.1016/j.cellsig.2013.12.015
CitationsScopus - 1Web of Science - 1
Co-authorsJohn Rostas, Nikki Verrills, Phil Dickson
2014Abdul Majeed ABB, Pearsall E, Carpenter H, Brzozowski J, Dickson PW, Rostas JAP, Skelding KA, 'CaMKII Kinase Activity, Targeting and Control of Cellular Functions: Effect of Single and Double Phosphorylation of CaMKIIa', Calcium Signaling, 1 36-51 (2014) [C1]
Co-authorsPhil Dickson, John Rostas
2014Bond DB, Brzozowski J, Skelding KA, Roselli SR, Weidenhofer J, 'Use of tetraspanins CD151 and CD9 as biomarkers for breast cancer', Breast Cancer Management, 3 123-126 (2014) [C3]
DOI10.2217/bmt.14.2
Co-authorsJudith Weidenhofer
2012Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253', JOURNAL OF NEUROCHEMISTRY, 123 31-31 (2012) [E3]
Author URL
Co-authorsJohn Rostas, Nikki Verrills, Phil Dickson
2012Majeed ABA, Rostas JAP, Carpenter H, Dickson PW, Skelding KA, 'Multi-site phosphorylation of CaMKII regulates CaMKII function co-operatively', JOURNAL OF NEUROCHEMISTRY, 123 116-116 (2012) [E3]
Author URL
Co-authorsPhil Dickson, John Rostas
2012Skelding KA, Barry RD, Shafren DR, 'Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride', Investigational New Drugs, 30 568-581 (2012) [C1]
CitationsScopus - 4Web of Science - 4
2012Skelding KA, Spratt NJ, Fluechter L, Dickson PW, Rostas JA, 'alpha CaMKII is differentially regulated in brain regions that exhibit differing sensitivities to ischemia and excitotoxicity', Journal of Cerebral Blood Flow and Metabolism, 32 2181-2192 (2012) [C1]
CitationsScopus - 5Web of Science - 6
Co-authorsJohn Rostas, Phil Dickson, Neil Spratt
2011Skelding KA, Rostas JA, Verrills NM, 'Controlling the cell cycle: The role of calcium/calmodulin-stimulated protein kinases I and II', Cell Cycle, 10 631-639 (2011) [C1]
DOI10.4161/cc.10.4.14798
CitationsScopus - 26Web of Science - 28
Co-authorsJohn Rostas, Nikki Verrills
2010Skelding KA, Suzuki T, Gordon SL, Xue J, Verrills NM, Dickson PW, Rostas JA, 'Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function', Cellular Signalling, 22 759-769 (2010) [C1]
DOI10.1016/j.cellsig.2009.12.011
CitationsScopus - 9Web of Science - 9
Co-authorsPhil Dickson, Nikki Verrills, John Rostas
2009Skelding KA, Barry RD, Shafren DR, 'Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21', Breast Cancer Research and Treatment, 113 21-30 (2009) [C1]
DOI10.1007/s10549-008-9899-2
CitationsScopus - 14Web of Science - 13
2009Skelding KA, Rostas JA, 'Regulation of CaMKII in vivo: The importance of targeting and the intracellular microenvironment', Neurochemical Research, 34 1792-1804 (2009) [C1]
DOI10.1007/s11064-009-9985-9
CitationsScopus - 22Web of Science - 23
Co-authorsJohn Rostas
2006Skelding KA, Hickey DK, Horvat JC, Bao SS, Roberts KG, Read JM, et al., 'Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection', Vaccine, 24 355-366 (2006) [C1]
DOI10.1016/j.vaccine.2005.07.104
CitationsScopus - 28Web of Science - 26
Co-authorsJay Horvat, Philip Hansbro
2004Howland LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, Hansbro PM, et al., 'Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection', Infection and Immunity, 72 1019-1028 (2004) [C1]
DOI10.1128/IAI.72.2.1019-1028.2004
CitationsScopus - 107Web of Science - 97
Co-authorsPhilip Hansbro
2004Hickey DK, Jones RC, Bao S, Blake AE, Skelding KA, Howland LJ, Beagley KW, 'Intranasal immunization with C.muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate', Vaccine, 22(31-32) 4306-4315 (2004) [C1]
DOI10.1016/j.vaccine.2004.04.021
CitationsScopus - 20Web of Science - 21
Show 12 more journal articles

Conference (27 outputs)

YearCitationAltmetricsLink
2014Yoon E-J, Chi MN, Enjeti AK, Verrills NM, Skelding KA, 'CHARACTERISING A NEW TARGET FOR THE TREATMENT OF ACUTE LEUKAEMIAS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsNikki Verrills
2013Skelding KA, Majeed ABA, Carpenter H, Dickson PW, Rostas JA, 'Can functional outcomes of CaMKII double phosphorylation be predicted from outcomes following single phosphorylation of CaMKII?', JOURNAL OF NEUROCHEMISTRY, Cancun, MEXICO (2013) [E3]
Author URL
Co-authorsJohn Rostas, Phil Dickson
2012Skelding KA, Abdul Majeed ABB, Dickson PW, Spratt NJ, Rostas JA, 'CAMKII is regulated differently in brains regions with differing sensitivities to ischaemia/excitotoxicity', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
Co-authorsPhil Dickson, Neil Spratt, John Rostas
2012Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Dephosphorylation of CAMKII at T253 controls progression through metaphase', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
Co-authorsJohn Rostas, Nikki Verrills, Phil Dickson
2012Abdul Majeed ABB, Skelding KA, Dickson PW, Rostas JA, 'Does phosphorylation of CaMKII at multiple sites regulate CaMKII targeting co-operatively or independently?', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
Co-authorsPhil Dickson, John Rostas
2012Rostas JA, Skelding KA, Fluechter L, Dickson PW, Spratt NJ, 'CaMKII is Differentially Regulated in Striatum and Cortex', JOURNAL OF NEUROCHEMISTRY (2012) [E3]
Author URL
Co-authorsJohn Rostas, Neil Spratt, Phil Dickson
2012Rostas JA, Skelding KA, Fluechter L, Dickson PW, Spratt NJ, 'CaMKII is differentially regulated in striatum and cortex', Journal of Molecular Neuroscience: Abstracts The 21st Annual Meeting of the Israel Society for Neuroscience & The First Binational Australian-Israeli Meeting in Neuroscience, Eilat, Israel (2012) [E3]
Co-authorsPhil Dickson, Neil Spratt, John Rostas
2011Skelding KA, Chung S, Pepperall D-G, Tomkins AJ, Spratt NJ, Rostas JA, 'The role of CaMKII in neuronal sensitivity to ischaemia', Oral abstracts. Australian Neuroscience Society Annual Meeting, Auckland, NZ (2011) [E3]
Co-authorsJohn Rostas, Neil Spratt
2010Rostas JA, Skelding KA, 'The role of targeting in the regulation of CaMKII in vivo', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology Symposium Abstracts, Melbourne, Vic (2010) [E3]
Co-authorsJohn Rostas
2010Skelding KA, Tomkins AJ, Fluechter L, Pepperall D-G, Spratt NJ, Rostas JA, 'Ischaemia-induced CaMKII phosphorylation in hypertensive and normotensive rats', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
Co-authorsJohn Rostas, Neil Spratt
2010Skelding KA, Verrills NM, Dickson PW, Rostas JA, 'Regulation of proliferation of neuroblastoma cells by CaMKII', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
Co-authorsNikki Verrills, John Rostas, Phil Dickson
2010Skelding KA, Xue J, Suzuki T, Verrills NM, Dickson PW, Rostas JA, 'Mechanisms of phosphorylation-sensitive CaMKII targeting', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
Co-authorsPhil Dickson, Nikki Verrills, John Rostas
2009Skelding KA, Liao X, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Functional consequences of CaMKII phosphorylation at THR253 in neurons', ANS 2009 Abstracts: Posters, Canberra, ACT (2009) [E3]
Co-authorsNikki Verrills, Phil Dickson, Alistair Sim, John Rostas
2009Rostas JA, Skelding KA, Liao X, Verrills NM, Dickson PW, 'Regulation of CaMKII by targeting', Proceedings of the 2nd Australia-China Biomedical Research Conference, - (2009) [E3]
Co-authorsNikki Verrills, John Rostas, Phil Dickson
2009Skelding KA, Liao X, Verrills NM, Fluechter L, Dickson PW, Rostas JA, 'CaMKII phosphorylation at T253 alters neuronal growth rates and morphology', Journal of Neurochemistry, Busan, Korea (2009) [E3]
DOI10.1111/j.1471-4159.2009.06238.x
Co-authorsNikki Verrills, John Rostas, Phil Dickson
2009Rostas JA, Skelding KA, Verrills NM, Suzuki PW, Dickson T, 'CaMKII binding partners vary with cell type and phosphorylation state', Journal of Neurochemistry, Busan, Korea (2009) [E3]
DOI10.1111/j.1471-4159.2009.06238.x
Co-authorsJohn Rostas, Nikki Verrills
2008Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Identification of CaMKII binding proteins in brain sensitive to CaMKII phosphorylation state', Proceedings of the Australian Neuroscience Society, Hobart, TAS (2008) [E3]
Co-authorsJohn Rostas, Nikki Verrills, Phil Dickson, Alistair Sim
2008Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Development of a novel method for the identification of CaMKII binding proteins', Journal of Neurochemistry, Shanghai, China (2008) [E3]
Co-authorsJohn Rostas, Nikki Verrills, Phil Dickson, Alistair Sim
2007Skelding KA, Johansson ES, Au GG, Barry RD, Shafren DR, 'CAVATAK TM has anti-cancer properties against human metastatic breast cancer', Fourth International Conference on Oncolytic Viruses as Cancer Therapeutics, Carefree, Arizona (2007) [E3]
Co-authorsGough Au
2006Au GG, Johansson ES, Berry L, Skelding KA, Haley ES, Barry RD, Shafren DR, 'Coxsackievirus A21 as an oncolytic virotherapy agent for human cancers', Northern Lights EUROPIC 2006, Inari, Finland (2006) [E3]
Co-authorsGough Au
2005Shafren DR, Au GG, Berry LJ, Haley ES, Skelding KA, Barry RD, 'The human enterovirus, Coxsackievirus A21, exhibits oncolytic activity across a spectrum of cancer types', Proceedings of the 96th American Association for Cancer Research Annual Meeting, Anaheim, California (2005) [E3]
Co-authorsGough Au
2005Skelding KA, Hickey DK, Horvat JC, Hansbro PM, Bao S, Beagley KW, 'Combined transcutaneous and intranasal immunisation protects against genital tract Chlamydial infection', Proceedings of the Twelfth International Congress of Mucosal Immunology, Boston, Massachusetts, USA. (2005) [E3]
Co-authorsJay Horvat, Philip Hansbro
2005Skelding KA, Hickey DK, Horvat JC, Hansbro PM, Bao S, Beagley KW, 'Comparison of intranasal and transcutaneous immunisation for the protection against Chlamydial pneumonia', Proceedings of the Twelfth International Congress of Mucosal Immunology, Boston, Massachusetts (2005) [E3]
Co-authorsJay Horvat, Philip Hansbro
2005Berry LJ, Haley ES, Skelding KA, Au GG, Barry RD, Shafren DR, 'Oncolytic activity of enteroviruses across a spectrum of human cancer types', Third Annual Australian Virology Group Meeting, Phillip Island, VIC (2005) [E3]
Co-authorsGough Au
2004Beagley KW, Skelding KA, Hickey DK, Roberts KG, Bao S, 'Combined transcutaneous and intranasal immunization protects against genital tract Chlamydia infection', American Journal of Reproductive Immunology, St Louis, Missouri (2004) [E3]
2004Skelding KA, Haley ES, Shafren DR, Barry RD, 'Viral oncolysis of human breast cancer', The Hunter Medical Research Institute Inaugural Cancer Conference, - (2004) [E3]
2003Berry L, Hickey DK, Skelding KA, Bao S, Hansbro PM, Beagley KW, 'Transcutaneous immunisation prevents Chlamydia muridarum genital tract infection', American Journal of Reproductive Immunology, - (2003) [E3]
Co-authorsPhilip Hansbro
Show 24 more conferences
Edit

Grants and Funding

Summary

Number of grants19
Total funding$1,247,243

Click on a grant title below to expand the full details for that specific grant.


20152 grants / $374,077

A novel biomarker for luminal B breast cancer$359,577

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamDoctor Nikki Verrills, Doctor Kathryn Skelding
SchemeResearch Grant
RoleInvestigator
Funding Start2015
Funding Finish2015
GNoG1400487
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Too Much of a Good Thing: Application for a triple-gas incubator to allow cell culture under normal conditions$14,500

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Craig Gedye, Professor Rodney Scott, Doctor Nikola Bowden, Doctor Simon Keely, Doctor Kathryn Skelding
SchemeResearch Grant
RoleInvestigator
Funding Start2015
Funding Finish2015
GNoG1500730
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20146 grants / $607,500

Tetraspanin CD9; more than just an exosome marker - A novel biomarker to target for prostate cancer$300,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jude Weidenhofer, Doctor Kathryn Skelding, Doctor Matt Dun, Ms Belinda Goldie, Miss Danielle Bond
SchemeProject Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1400921
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Identification of BAALC as a new target for the treatment of acute myeloid leukaemia$200,000

Funding body: Cancer Australia

Funding bodyCancer Australia
Project TeamDoctor Kathryn Skelding
SchemePriority-driven Collaborative Cancer Research Scheme
RoleLead
Funding Start2014
Funding Finish2014
GNoG1300551
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Developing Synthetic Exosomes to Target and Deliver Anti-Cancer Agents to Prostate Cancer Cells$37,500

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamMr Joshua Brzozowski, Doctor Jude Weidenhofer, Doctor Kathryn Skelding
SchemePostgraduate Research Scholarship
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1401405
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Myr-C310: A new treatment for childhood leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kathryn Skelding, Doctor Nikki Verrills
SchemeProject Grant
RoleLead
Funding Start2014
Funding Finish2014
GNoG1301349
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Preclinical testing of a novel therapeutic strategy for breast cancer $25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikki Verrills, Doctor Kathryn Skelding
SchemeProject Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1301439
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Identification of BAALC as a new target for the treatment of acute myeloid leukaemia $20,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Kathryn Skelding, Doctor Nikki Verrills
SchemeNear Miss Grant
RoleLead
Funding Start2014
Funding Finish2014
GNoG1301404
Type Of FundingInternal
CategoryINTE
UONY

20132 grants / $49,596

Targeting BAALC as a new treatment for acute myeloid leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kathryn Skelding, Doctor Nikki Verrills
SchemeProject Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1301348
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20123 grants / $55,570

Microscopic illumination system for advanced fluorescent protein technology$34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamDoctor Rick Thorne, Professor Xu Dong Zhang, Conjoint Associate Professor Murray Cairns, Doctor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli, Doctor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck
SchemeEquipment Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1100983
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

Regulation of the cell cycle by phosphorylation dependent targeting of CaMKII$20,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Nikki Verrills, Doctor Kathryn Skelding, Emeritus Professor John Rostas, Associate Professor Phillip Dickson, Conjoint Professor Keith Jones
SchemeNear Miss Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1200679
Type Of FundingInternal
CategoryINTE
UONY

The 11th Biennial meeting of the Asian Pacific Society for Neurochemistry and the 55th Annual meeting of the Japanese Society for Neurochemistry, Kobe Conference Centre, 30 September - 2 October 2012$1,570

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding bodyUniversity of Newcastle - Faculty of Health and Medicine
Project TeamDoctor Kathryn Skelding
SchemeTravel Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1201010
Type Of FundingInternal
CategoryINTE
UONY

20113 grants / $63,200

Regulation of Breast Cancer Growth by a Novel Phosphorylation-Dependent Targeting Mechanism$35,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kathryn Skelding, Doctor Nikki Verrills, Emeritus Professor John Rostas
SchemeBreast Cancer Project Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1001005
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Role of CaMKII targeting in stroke susceptibility and outcome$18,200

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamEmeritus Professor John Rostas, Doctor Neil Spratt, Doctor Kathryn Skelding
SchemeStroke Research Project Grant
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1001013
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

IMPLEN NanoPhotometer pearl$10,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamConjoint Associate Professor Murray Cairns, Associate Professor Paul Tooney, Professor Alan Brichta, Emeritus Professor John Rostas, Emeritus Professor Patricia Michie, Conjoint Professor Keith Jones, Professor Ulli Schall, Associate Professor Phillip Dickson, Doctor Frederick Walker, Doctor Rick Thorne, Doctor Chris Dayas, Doctor Nikki Verrills, Doctor Janet Holt, Doctor Severine Roselli, Doctor Kathryn Skelding, Doctor Jude Weidenhofer, Associate Professor Liz Milward, Doctor Charles De Bock, Doctor Julie Merriman-Jones, Doctor Jing Qin Wu, Doctor Bing Liu, Mr Dan Johnstone, Ms Belinda Goldie, Doctor Natalie Beveridge
SchemeEquipment Grant
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1100030
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

20101 grants / $34,000

ABI 7500 Real Time PCR System $34,000

Funding body: NHMRC (National Health & Medical Research Council)

20091 grants / $1,700

The 22nd Biennial Meeting of the ISN/APSN Joint Meeting, Busan South Korea, 23-28 August 2009$1,700

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding bodyUniversity of Newcastle - Faculty of Health and Medicine
Project TeamDoctor Kathryn Skelding
SchemeTravel Grant
RoleLead
Funding Start2009
Funding Finish2009
GNoG0190587
Type Of FundingInternal
CategoryINTE
UONY

20051 grants / $61,600

Viral Oncolysis of Human Breast Cancer$61,600

Funding body: National Breast Cancer Foundation

Funding bodyNational Breast Cancer Foundation
Project TeamDoctor Kathryn Skelding
SchemePostgraduate Research Scholarship
RoleLead
Funding Start2005
Funding Finish2005
GNoG0184441
Type Of FundingDonation - Aust Non Government
Category3AFD
UONY
Edit

Research Supervision

Current Supervision

CommencedResearch Title / Program / Supervisor Type
2015PPP2R2A - A Novel Biomarker and Therapeutic Target for Luminal B Breast Cancer
Medical Science, Faculty of Health and Medicine
Co-Supervisor
2014Identification of Biomarkers and Novel Targets for Prostate Cancer from Exosomes
Medical Science, Faculty of Health and Medicine
Co-Supervisor
2014Developing Synthetic Exosomes to Target and Deliver Anti-Cancer Agents to Prostate Cancer Cells
Medical Science, Faculty of Health and Medicine
Co-Supervisor

Past Supervision

YearResearch Title / Program / Supervisor Type
2013Effects of Multi-site Phosphorylation on CaMKII Function
Medical Science, Faculty of Health and Medicine
Co-Supervisor
Edit

News

Pablo Moscato small

Debunking myths about cancer

February 4, 2014

University of Newcastle researchers are debunking myths as they pave the way forward in cancer research.

Dr Kathryn Skelding

Position

Lecturer
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Medical Biochemistry

Contact Details

Emailkathryn.skelding@newcastle.edu.au
Phone(02) 4921 5982
Fax(02) 4921 6903

Office

RoomLS3-41
BuildingLife Sciences
LocationCallaghan
University Drive
Callaghan, NSW 2308
Australia
Edit